SlideShare a Scribd company logo
Compliance with
Narcotics Guidelines
        April 10-12, 2012
 Walt Disney World Swan Resort
Accepted Learning Objectives:
1.  Describe how managed care programs, employers, health
    care providers and insurers are susceptible to increased
    workers compensation costs due to prescription drug abuse.

2.  Identify strategies employers and medical professionals can
    use to help drug-dependent and addicted employees regain
    control of their lives and return to work using results of
    CompPharma’s survey, “Prescription Drug Management in
    Workers’ Compensation – The Eighth Annual Survey.”

3.  Describe how Washington State has addressed the over use
    of opioids in workers’ compensation.
Disclosure Statement
•  Joseph Paduda has disclosed that he
   has a relationship with Reckitt
   Benckiser’s Suboxone Sublingual Film.
•  Dr. Richard A. Victor has disclosed no
   relevant, real or apparent personal or
   professional financial relationships.
Narcotics Use And
Compliance With
   Guidelines
 Richard Victor, J.D., Ph.D.
    Executive Director
  Workers Compensation
     Research Institute
Today s Outline
•  About heath care in workers
   compensation
•  Relevant findings from 2 WCRI studies
•  About WCRI
About Workers Compensation
•  Century-old social program
•  Injured workers receive medical care, income
   benefits, rehabilitation
•  Patients entitled by law to all necessary care
•  Patients have no deductibles or copayments,
   no formularies or step therapy
•  Physician dispensing is common in a growing
   number of states
•  Prices near AWP
Workers Compensation Facts
•  Employers pay $79 billion in 2008
•  Medical care represents more than
   half of the cost
•  4.6 million work-injuries
•  2.3 million involve lost time from work
•  20% of total—lost more than 1 week
   from work
•  Median lost time is 16 weeks
Common Medical Conditions In
  Workers Compensation
Medical Condition                              % Of Cases
Spine conditions
   Sprain, strain and nonspecific spine pain      21%
   Neurologic spine pain                          7%
Other musculoskeletal conditions
   Non-spine sprain and strain                    15%
   Shoulder inflammation                          7%
   Knee derangement                               4%
   Carpal tunnel syndrome                         2%
Trauma
   Fractures                                      10%
   Laceration or contusion                        12%
Other conditions                                  21%


            Cases With > 7 Days Of Lost Time
Today s Outline
•  About heath care in workers
   compensation
 Relevant findings from 2 WCRI studies
•  About WCRI
Two WCRI Studies Of Area
Variations In Prescribing Patterns
Major Findings From
WCRI Narcotics Studies
Data
•  Nonsurgical cases
•  Patients lost more than 1 week from work
•  Results presented for episodes of
   disability
•  Snapshot at an average of 24 months
   after injury
Data
•  17 states that represent more than 60%
   of WC benefits in the U.S.
•  360,000 Rx for 75,000 nonsurgical
   episodes of disability
•  16% to 50% of all episodes in each
   state
Most Patients Get Rx Pain Medication




   Nonsurgical Claims With > 7 Days Of Lost Time,
   Injuries From October 2005 To September 2006,
       Prescriptions Filled Through March 2008
Most Patients Get Narcotics




Nonsurgical Claims With > 7 Days Of Lost Time,
Injuries From October 2005 To September 2006,
    Prescriptions Filled Through March 2008
Unusually High Use Of Narcotics
   In NY, LA, PA, And MA




 Nonsurgical Claims With > 7 Days Of Lost Time,
 Injuries From October 2005 To September 2006,
     Prescriptions Filled Through March 2008
Also Higher Use Of Narcotics
  In CA, MD, NC, And TX




Nonsurgical Claims With > 7 Days Of Lost Time,
Injuries From October 2005 To September 2006,
    Prescriptions Filled Through March 2008
Average Worker In Four States Had More
 Narcotic Pills Per Episode Of Disability




   Nonsurgical Claims With > 7 Days Of Lost Time,
   Injuries From October 2005 To September 2006,
       Prescriptions Filled Through March 2008
Practice Patterns Favor Schedule II Narcotics
     In Northeast & Mid-Atlantic States




   Nonsurgical Claims With > 7 Days Of Lost Time,
   Injuries From October 2005 To September 2006,
       Prescriptions Filled Through March 2008
Major Findings From
WCRI Narcotics Studies
Longer-Term Use Of Narcotics
•  Study definition
  –  First narcotic Rx filled within first 3 months
     after injury
  –  Narcotics continued after 6 months
     post-injury
  –  3+ Rx fills during months 7–12
•  Nonsurgical cases
Longer-Term Use Common
 In Louisiana And New York




Nonsurgical Claims With > 7 Days Of Lost Time,
Injuries From October 2005 To September 2006,
    Prescriptions Filled Through March 2008
Longer-Term Use Also More Likely
   In PA, TX, CA, MA, And NC




 Nonsurgical Claims With > 7 Days Of Lost Time,
 Injuries From October 2005 To September 2006,
     Prescriptions Filled Through March 2008
VeryModest Interstate Variation In At
     Substantial Interstate Variation
    Substantial Interstate Variation
Median MEUs 90thEpisode of Disability
         The Per Percentile
                                                  50th Percentile      75th Percentile         90th Percentile
Morphine Equivalent Units Per Claim




                                  Nonsurgical Claims With > 7 Days Of Lost Time That Were
                                 Identified As Longer-Term Users Of Narcotics, Injuries From
                                    October 2005 To September 2006, Prescriptions Filled
                                                    Through March 2008
Common Guideline Recommendations
  For Monitoring & Management
Few Longer-Term Users Received
Services For Monitoring/Management




 Nonsurgical Claims With > 7 Days Of Lost Time That Were
Identified As Longer-Term Users Of Narcotics, Injuries From
   October 2005 To September 2006, Prescriptions Filled
                   Through March 2008
Few Longer-Term Users Received
Services For Monitoring/Management




 Nonsurgical Claims With > 7 Days Of Lost Time That Were
Identified As Longer-Term Users Of Narcotics, Injuries From
   October 2005 To September 2006, Prescriptions Filled
                   Through March 2008
Today s Outline
•  About heath care in workers
   compensation
•  Relevant findings from 2 WCRI studies
 About WCRI
About WCRI
•  Nation s largest independent think
   tank on workers compensation public
   policy issues
•  Published hundreds of peer-reviewed
   studies since founding in 1983
•  Membership organization—diverse
•  Not make recommendations nor take
   positions on issues
About WCRI: Focus Of Current
Health Policy Research Agenda
About WCRI: Focus Of Current
Health Policy Research Agenda
Today s Outline

More Related Content

What's hot

Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...
Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...
Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...
University of Michigan Department of Emergency Medicine
 
Medical Marijuana in Canada - Has Everything Changed?
Medical Marijuana in Canada - Has Everything Changed?Medical Marijuana in Canada - Has Everything Changed?
Medical Marijuana in Canada - Has Everything Changed?
Canadian Cancer Survivor Network
 
Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015
Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015
Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015
American Academy of Family Physicians
 
Rare Disease access issues 2015 v2
Rare Disease access issues 2015 v2Rare Disease access issues 2015 v2
Rare Disease access issues 2015 v2
Canadian Organization for Rare Disorders
 
Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access BriefingMichael Jacobson
 
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroWeb only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
OPUNITE
 
Drug Access Navigation - An Insider's Perspective
Drug Access Navigation - An Insider's PerspectiveDrug Access Navigation - An Insider's Perspective
Drug Access Navigation - An Insider's Perspective
Canadian Cancer Survivor Network
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
OPUNITE
 
A Brief History of the CDFI
A Brief History of the CDFIA Brief History of the CDFI
A Brief History of the CDFI
Canadian Organization for Rare Disorders
 
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4travenRx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
OPUNITE
 
Pdmp 5 hopkins dreyzehner_o_leary
Pdmp 5 hopkins dreyzehner_o_learyPdmp 5 hopkins dreyzehner_o_leary
Pdmp 5 hopkins dreyzehner_o_leary
OPUNITE
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
Canadian Organization for Rare Disorders
 
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Canadian Organization for Rare Disorders
 
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Canadian Organization for Rare Disorders
 
The Feds Are Coming! Session One: The Rules Have Changed
The Feds Are Coming! Session One: The Rules Have ChangedThe Feds Are Coming! Session One: The Rules Have Changed
The Feds Are Coming! Session One: The Rules Have Changed
Polsinelli PC
 
Rx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisherRx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisher
OPUNITE
 
Prescriptive Authority
Prescriptive AuthorityPrescriptive Authority
Prescriptive Authoritybodo-con
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canadian Organization for Rare Disorders
 
Accessibility of medical marijuana
Accessibility of medical marijuanaAccessibility of medical marijuana
Accessibility of medical marijuana
JonathanJuca
 
How Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in CanadaHow Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in Canada
Canadian Cancer Survivor Network
 

What's hot (20)

Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...
Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...
Story to Sepsis Screen: A Journey in the Details by Elizabeth R. Alpern, MD, ...
 
Medical Marijuana in Canada - Has Everything Changed?
Medical Marijuana in Canada - Has Everything Changed?Medical Marijuana in Canada - Has Everything Changed?
Medical Marijuana in Canada - Has Everything Changed?
 
Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015
Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015
Prescription Drug Abuse, Daniel Blaney-Koen - SLC 2015
 
Rare Disease access issues 2015 v2
Rare Disease access issues 2015 v2Rare Disease access issues 2015 v2
Rare Disease access issues 2015 v2
 
Canada Market Access Briefing
Canada Market Access BriefingCanada Market Access Briefing
Canada Market Access Briefing
 
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiroWeb only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
Web only rx16 pdmp-tues_330_1_kreiner_2ringwalt-schiro
 
Drug Access Navigation - An Insider's Perspective
Drug Access Navigation - An Insider's PerspectiveDrug Access Navigation - An Insider's Perspective
Drug Access Navigation - An Insider's Perspective
 
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldbergerRx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
Rx16 pdmp wed_200_1_frick_2zadrazil_3delcher-goldberger
 
A Brief History of the CDFI
A Brief History of the CDFIA Brief History of the CDFI
A Brief History of the CDFI
 
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4travenRx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
Rx16 pdmp tues_1230_1_small_2kreiner_3baumgartner_4traven
 
Pdmp 5 hopkins dreyzehner_o_leary
Pdmp 5 hopkins dreyzehner_o_learyPdmp 5 hopkins dreyzehner_o_leary
Pdmp 5 hopkins dreyzehner_o_leary
 
Funding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program PerspectiveFunding of Drugs for Rare Diseases Provincial Program Perspective
Funding of Drugs for Rare Diseases Provincial Program Perspective
 
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
Evidence-Based Approach to Assuring Value for Orphan Drugs: Pam Gavin (NORD)
 
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...Ocular gene transfer:Developing an ethical framework to communicate clinical ...
Ocular gene transfer:Developing an ethical framework to communicate clinical ...
 
The Feds Are Coming! Session One: The Rules Have Changed
The Feds Are Coming! Session One: The Rules Have ChangedThe Feds Are Coming! Session One: The Rules Have Changed
The Feds Are Coming! Session One: The Rules Have Changed
 
Rx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisherRx16 tpp tues_200_1_bartlett-peak_2fisher
Rx16 tpp tues_200_1_bartlett-peak_2fisher
 
Prescriptive Authority
Prescriptive AuthorityPrescriptive Authority
Prescriptive Authority
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
 
Accessibility of medical marijuana
Accessibility of medical marijuanaAccessibility of medical marijuana
Accessibility of medical marijuana
 
How Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in CanadaHow Prescription Drugs are Approved in Canada
How Prescription Drugs are Approved in Canada
 

Viewers also liked

Rollin Gallagher
Rollin GallagherRollin Gallagher
Rollin Gallagher
OPUNITE
 
Mike Townsend
Mike TownsendMike Townsend
Mike Townsend
OPUNITE
 
Carol Boyd
Carol BoydCarol Boyd
Carol Boyd
OPUNITE
 
Robert Sproul
Robert SproulRobert Sproul
Robert Sproul
OPUNITE
 
Gary Martin2
Gary Martin2Gary Martin2
Gary Martin2
OPUNITE
 
Joseph Paduda
Joseph PadudaJoseph Paduda
Joseph Paduda
OPUNITE
 
Sarah Melton
Sarah MeltonSarah Melton
Sarah Melton
OPUNITE
 
Michael-Ward
Michael-WardMichael-Ward
Michael-Ward
OPUNITE
 
Leslie Balonick
Leslie BalonickLeslie Balonick
Leslie Balonick
OPUNITE
 
Michelle Lipinski
Michelle LipinskiMichelle Lipinski
Michelle Lipinski
OPUNITE
 
CLAAD/ Safe BTW
CLAAD/ Safe BTWCLAAD/ Safe BTW
CLAAD/ Safe BTW
OPUNITE
 
Gary Franklin
Gary FranklinGary Franklin
Gary Franklin
OPUNITE
 
Benson-Marshall-Matthew
Benson-Marshall-MatthewBenson-Marshall-Matthew
Benson-Marshall-Matthew
OPUNITE
 
Alex Cahana
Alex CahanaAlex Cahana
Alex Cahana
OPUNITE
 
Dr. Ileana Arias
Dr. Ileana AriasDr. Ileana Arias
Dr. Ileana Arias
OPUNITE
 
Karen Perry
Karen PerryKaren Perry
Karen Perry
OPUNITE
 
Kelly Clark
Kelly ClarkKelly Clark
Kelly Clark
OPUNITE
 
Heuser-Desmond
Heuser-DesmondHeuser-Desmond
Heuser-Desmond
OPUNITE
 
Andrew Kolodny
Andrew KolodnyAndrew Kolodny
Andrew Kolodny
OPUNITE
 

Viewers also liked (20)

Rollin Gallagher
Rollin GallagherRollin Gallagher
Rollin Gallagher
 
Mike Townsend
Mike TownsendMike Townsend
Mike Townsend
 
Carol Boyd
Carol BoydCarol Boyd
Carol Boyd
 
Robert Sproul
Robert SproulRobert Sproul
Robert Sproul
 
Ismposter
Ismposter Ismposter
Ismposter
 
Gary Martin2
Gary Martin2Gary Martin2
Gary Martin2
 
Joseph Paduda
Joseph PadudaJoseph Paduda
Joseph Paduda
 
Sarah Melton
Sarah MeltonSarah Melton
Sarah Melton
 
Michael-Ward
Michael-WardMichael-Ward
Michael-Ward
 
Leslie Balonick
Leslie BalonickLeslie Balonick
Leslie Balonick
 
Michelle Lipinski
Michelle LipinskiMichelle Lipinski
Michelle Lipinski
 
CLAAD/ Safe BTW
CLAAD/ Safe BTWCLAAD/ Safe BTW
CLAAD/ Safe BTW
 
Gary Franklin
Gary FranklinGary Franklin
Gary Franklin
 
Benson-Marshall-Matthew
Benson-Marshall-MatthewBenson-Marshall-Matthew
Benson-Marshall-Matthew
 
Alex Cahana
Alex CahanaAlex Cahana
Alex Cahana
 
Dr. Ileana Arias
Dr. Ileana AriasDr. Ileana Arias
Dr. Ileana Arias
 
Karen Perry
Karen PerryKaren Perry
Karen Perry
 
Kelly Clark
Kelly ClarkKelly Clark
Kelly Clark
 
Heuser-Desmond
Heuser-DesmondHeuser-Desmond
Heuser-Desmond
 
Andrew Kolodny
Andrew KolodnyAndrew Kolodny
Andrew Kolodny
 

Similar to Richard Victor

State Strategies for Administrative Simplification
State Strategies for Administrative SimplificationState Strategies for Administrative Simplification
State Strategies for Administrative Simplification
American Academy of Family Physicians
 
Rx15 tpp tues_1230_allen-emptage
Rx15 tpp tues_1230_allen-emptageRx15 tpp tues_1230_allen-emptage
Rx15 tpp tues_1230_allen-emptage
OPUNITE
 
Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...
Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...
Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...
American Academy of Family Physicians
 
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramseyRx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
OPUNITE
 
원격 의료 산업의 글로벌 동향 및 주요 이슈
원격 의료 산업의 글로벌 동향 및 주요 이슈원격 의료 산업의 글로벌 동향 및 주요 이슈
원격 의료 산업의 글로벌 동향 및 주요 이슈
Yoon Sup Choi
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williams
OPUNITE
 
Shannon_Zhang_Project_Presentation_Disclaimer_Credits
Shannon_Zhang_Project_Presentation_Disclaimer_CreditsShannon_Zhang_Project_Presentation_Disclaimer_Credits
Shannon_Zhang_Project_Presentation_Disclaimer_CreditsShannon-Xiaohan Zhang MS
 
Rx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinnerRx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinner
OPUNITE
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?
RIAPA
 
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Canadian Organization for Rare Disorders
 
Cost saving strategies_updated
Cost saving strategies_updatedCost saving strategies_updated
Cost saving strategies_updated
OPUNITE
 
FLAACOs 2014 Conference - CVS Health: Collaborating with Providers
FLAACOs 2014 Conference - CVS Health: Collaborating with ProvidersFLAACOs 2014 Conference - CVS Health: Collaborating with Providers
FLAACOs 2014 Conference - CVS Health: Collaborating with Providers
MARCYINC
 
New mexicoap npp
New mexicoap nppNew mexicoap npp
New mexicoap npp
DoraWong10
 
Telehealth Regulatory Potential Across State Lines
Telehealth Regulatory Potential Across State LinesTelehealth Regulatory Potential Across State Lines
Telehealth Regulatory Potential Across State Lines
Virginia Rural Health Association
 
Rx15 tpp wed_300_1_paduda-white_2hanna
Rx15 tpp wed_300_1_paduda-white_2hannaRx15 tpp wed_300_1_paduda-white_2hanna
Rx15 tpp wed_300_1_paduda-white_2hanna
OPUNITE
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notes
OPUNITE
 
Midlevel Operations: Exploring New Expsoures with Allied Health Providers
Midlevel Operations: Exploring New Expsoures with Allied Health ProvidersMidlevel Operations: Exploring New Expsoures with Allied Health Providers
Midlevel Operations: Exploring New Expsoures with Allied Health Providers
Sedgwick
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
OPUNITE
 
Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...
Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...
Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...
University of Michigan Injury Center
 

Similar to Richard Victor (20)

State Strategies for Administrative Simplification
State Strategies for Administrative SimplificationState Strategies for Administrative Simplification
State Strategies for Administrative Simplification
 
Rx15 tpp tues_1230_allen-emptage
Rx15 tpp tues_1230_allen-emptageRx15 tpp tues_1230_allen-emptage
Rx15 tpp tues_1230_allen-emptage
 
Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...
Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...
Administrative Burden: Legislative and Regulatory Advocacy to Improve Physici...
 
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramseyRx15 pdmp wed_430_1_stanton_2blake_3ramsey
Rx15 pdmp wed_430_1_stanton_2blake_3ramsey
 
원격 의료 산업의 글로벌 동향 및 주요 이슈
원격 의료 산업의 글로벌 동향 및 주요 이슈원격 의료 산업의 글로벌 동향 및 주요 이슈
원격 의료 산업의 글로벌 동향 및 주요 이슈
 
Rx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williamsRx16 tpp tues_1230_1_worthy_2williams
Rx16 tpp tues_1230_1_worthy_2williams
 
Shannon_Zhang_Project_Presentation_Disclaimer_Credits
Shannon_Zhang_Project_Presentation_Disclaimer_CreditsShannon_Zhang_Project_Presentation_Disclaimer_Credits
Shannon_Zhang_Project_Presentation_Disclaimer_Credits
 
Rx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinnerRx15 tpp wed_1115_2_fisher_3skinner
Rx15 tpp wed_1115_2_fisher_3skinner
 
Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?Controlled Substance Prescribing: What to Do?
Controlled Substance Prescribing: What to Do?
 
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1: 2:45pm- 4:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
 
Twillman preventing rx abuse
Twillman preventing rx abuseTwillman preventing rx abuse
Twillman preventing rx abuse
 
Cost saving strategies_updated
Cost saving strategies_updatedCost saving strategies_updated
Cost saving strategies_updated
 
FLAACOs 2014 Conference - CVS Health: Collaborating with Providers
FLAACOs 2014 Conference - CVS Health: Collaborating with ProvidersFLAACOs 2014 Conference - CVS Health: Collaborating with Providers
FLAACOs 2014 Conference - CVS Health: Collaborating with Providers
 
New mexicoap npp
New mexicoap nppNew mexicoap npp
New mexicoap npp
 
Telehealth Regulatory Potential Across State Lines
Telehealth Regulatory Potential Across State LinesTelehealth Regulatory Potential Across State Lines
Telehealth Regulatory Potential Across State Lines
 
Rx15 tpp wed_300_1_paduda-white_2hanna
Rx15 tpp wed_300_1_paduda-white_2hannaRx15 tpp wed_300_1_paduda-white_2hanna
Rx15 tpp wed_300_1_paduda-white_2hanna
 
Rx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notesRx15 workshop mon_200_aleshire_dowell_no_notes
Rx15 workshop mon_200_aleshire_dowell_no_notes
 
Midlevel Operations: Exploring New Expsoures with Allied Health Providers
Midlevel Operations: Exploring New Expsoures with Allied Health ProvidersMidlevel Operations: Exploring New Expsoures with Allied Health Providers
Midlevel Operations: Exploring New Expsoures with Allied Health Providers
 
Rx16 claad tue-vision_final
Rx16 claad tue-vision_finalRx16 claad tue-vision_final
Rx16 claad tue-vision_final
 
Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...
Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...
Prescription Drug Poisoning: No Longer a Silent Epidemic by Christy Porucznik...
 

More from OPUNITE

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
OPUNITE
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
OPUNITE
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
OPUNITE
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
OPUNITE
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
OPUNITE
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
OPUNITE
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
OPUNITE
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
OPUNITE
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
OPUNITE
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
OPUNITE
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
OPUNITE
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
OPUNITE
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
OPUNITE
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
OPUNITE
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
OPUNITE
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
OPUNITE
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
OPUNITE
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
OPUNITE
 

More from OPUNITE (20)

Dr. Tom Frieden keynote
Dr. Tom Frieden keynoteDr. Tom Frieden keynote
Dr. Tom Frieden keynote
 
Dr. Francis Collins keynote
Dr. Francis Collins keynoteDr. Francis Collins keynote
Dr. Francis Collins keynote
 
Kana Enomoto keynote
Kana Enomoto keynoteKana Enomoto keynote
Kana Enomoto keynote
 
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinnerRx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
Rx16 tpp wed_330_1_stack_2nelson_3roberts_4skinner
 
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershingWeb rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
Web rx16 prev_tues_330_1_lawal_2warren_3huddleston_4pershing
 
Rx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copyRx16 general session_wed_800_1_volkow copy
Rx16 general session_wed_800_1_volkow copy
 
Rx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelliRx16 general session_900_1_botticelli
Rx16 general session_900_1_botticelli
 
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copyWeb rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
Web rx16 prev_tues_200_1_bretthaude-mueller_2scott_3debenedittis_4cairnes copy
 
Rx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsenRx16 treat wed_330_1_barnes_2clarkolsen
Rx16 treat wed_330_1_barnes_2clarkolsen
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategiesRx16 prev wed_330_workplace issues and strategies
Rx16 prev wed_330_workplace issues and strategies
 
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harlessWeb only rx16 pharma-wed_330_1_shelley_2atwood-harless
Web only rx16 pharma-wed_330_1_shelley_2atwood-harless
 
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichtingRx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
Rx16 pdmp wed_330_1_hoppe_2sun_3baumgartner-leichting
 
Rx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2priceRx16 len wed_330_1_ferdinand_2price
Rx16 len wed_330_1_ferdinand_2price
 
Rx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earleRx16 heroin wed_330_1_rader_2lynch-earle
Rx16 heroin wed_330_1_rader_2lynch-earle
 
Rx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblattRx16 clinical wed_330_1_saunders_2wexelblatt
Rx16 clinical wed_330_1_saunders_2wexelblatt
 
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4deanWeb only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
Web only rx16-adv_tues_330_1_elliott_2brunson_3willis_4dean
 
Rx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_millerRx16 treat wed_200_group_falkinburg_miller
Rx16 treat wed_200_group_falkinburg_miller
 
Rx16 tpp wed_200_group
Rx16 tpp wed_200_groupRx16 tpp wed_200_group
Rx16 tpp wed_200_group
 
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnoldRx16 prevent wed_200_1_cairnes-wertnepy_2arnold
Rx16 prevent wed_200_1_cairnes-wertnepy_2arnold
 

Recently uploaded

655264371-checkpoint-science-past-papers-april-2023.pdf
655264371-checkpoint-science-past-papers-april-2023.pdf655264371-checkpoint-science-past-papers-april-2023.pdf
655264371-checkpoint-science-past-papers-april-2023.pdf
morearsh02
 
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...
beulahfernandes8
 
how to sell pi coins on Binance exchange
how to sell pi coins on Binance exchangehow to sell pi coins on Binance exchange
how to sell pi coins on Binance exchange
DOT TECH
 
Financial Assets: Debit vs Equity Securities.pptx
Financial Assets: Debit vs Equity Securities.pptxFinancial Assets: Debit vs Equity Securities.pptx
Financial Assets: Debit vs Equity Securities.pptx
Writo-Finance
 
what is a pi whale and how to access one.
what is a pi whale and how to access one.what is a pi whale and how to access one.
what is a pi whale and how to access one.
DOT TECH
 
BYD SWOT Analysis and In-Depth Insights 2024.pptx
BYD SWOT Analysis and In-Depth Insights 2024.pptxBYD SWOT Analysis and In-Depth Insights 2024.pptx
BYD SWOT Analysis and In-Depth Insights 2024.pptx
mikemetalprod
 
Webinar Exploring DORA for Fintechs - Simont Braun
Webinar Exploring DORA for Fintechs - Simont BraunWebinar Exploring DORA for Fintechs - Simont Braun
Webinar Exploring DORA for Fintechs - Simont Braun
FinTech Belgium
 
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...
Vighnesh Shashtri
 
The new type of smart, sustainable entrepreneurship and the next day | Europe...
The new type of smart, sustainable entrepreneurship and the next day | Europe...The new type of smart, sustainable entrepreneurship and the next day | Europe...
The new type of smart, sustainable entrepreneurship and the next day | Europe...
Antonis Zairis
 
234Presentation on Indian Debt Market.ppt
234Presentation on Indian Debt Market.ppt234Presentation on Indian Debt Market.ppt
234Presentation on Indian Debt Market.ppt
PravinPatil144525
 
how to sell pi coins on Bitmart crypto exchange
how to sell pi coins on Bitmart crypto exchangehow to sell pi coins on Bitmart crypto exchange
how to sell pi coins on Bitmart crypto exchange
DOT TECH
 
APP I Lecture Notes to students 0f 4the year
APP I  Lecture Notes  to students 0f 4the yearAPP I  Lecture Notes  to students 0f 4the year
APP I Lecture Notes to students 0f 4the year
telilaalilemlem
 
how to sell pi coins at high rate quickly.
how to sell pi coins at high rate quickly.how to sell pi coins at high rate quickly.
how to sell pi coins at high rate quickly.
DOT TECH
 
Isios-2024-Professional-Independent-Trustee-Survey.pdf
Isios-2024-Professional-Independent-Trustee-Survey.pdfIsios-2024-Professional-Independent-Trustee-Survey.pdf
Isios-2024-Professional-Independent-Trustee-Survey.pdf
Henry Tapper
 
The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.
DOT TECH
 
Introduction to Indian Financial System ()
Introduction to Indian Financial System ()Introduction to Indian Financial System ()
Introduction to Indian Financial System ()
Avanish Goel
 
USDA Loans in California: A Comprehensive Overview.pptx
USDA Loans in California: A Comprehensive Overview.pptxUSDA Loans in California: A Comprehensive Overview.pptx
USDA Loans in California: A Comprehensive Overview.pptx
marketing367770
 
when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.
DOT TECH
 
what is the future of Pi Network currency.
what is the future of Pi Network currency.what is the future of Pi Network currency.
what is the future of Pi Network currency.
DOT TECH
 
PF-Wagner's Theory of Public Expenditure.pptx
PF-Wagner's Theory of Public Expenditure.pptxPF-Wagner's Theory of Public Expenditure.pptx
PF-Wagner's Theory of Public Expenditure.pptx
GunjanSharma28848
 

Recently uploaded (20)

655264371-checkpoint-science-past-papers-april-2023.pdf
655264371-checkpoint-science-past-papers-april-2023.pdf655264371-checkpoint-science-past-papers-april-2023.pdf
655264371-checkpoint-science-past-papers-april-2023.pdf
 
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...
Exploring Abhay Bhutada’s Views After Poonawalla Fincorp’s Collaboration With...
 
how to sell pi coins on Binance exchange
how to sell pi coins on Binance exchangehow to sell pi coins on Binance exchange
how to sell pi coins on Binance exchange
 
Financial Assets: Debit vs Equity Securities.pptx
Financial Assets: Debit vs Equity Securities.pptxFinancial Assets: Debit vs Equity Securities.pptx
Financial Assets: Debit vs Equity Securities.pptx
 
what is a pi whale and how to access one.
what is a pi whale and how to access one.what is a pi whale and how to access one.
what is a pi whale and how to access one.
 
BYD SWOT Analysis and In-Depth Insights 2024.pptx
BYD SWOT Analysis and In-Depth Insights 2024.pptxBYD SWOT Analysis and In-Depth Insights 2024.pptx
BYD SWOT Analysis and In-Depth Insights 2024.pptx
 
Webinar Exploring DORA for Fintechs - Simont Braun
Webinar Exploring DORA for Fintechs - Simont BraunWebinar Exploring DORA for Fintechs - Simont Braun
Webinar Exploring DORA for Fintechs - Simont Braun
 
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...
Empowering the Unbanked: The Vital Role of NBFCs in Promoting Financial Inclu...
 
The new type of smart, sustainable entrepreneurship and the next day | Europe...
The new type of smart, sustainable entrepreneurship and the next day | Europe...The new type of smart, sustainable entrepreneurship and the next day | Europe...
The new type of smart, sustainable entrepreneurship and the next day | Europe...
 
234Presentation on Indian Debt Market.ppt
234Presentation on Indian Debt Market.ppt234Presentation on Indian Debt Market.ppt
234Presentation on Indian Debt Market.ppt
 
how to sell pi coins on Bitmart crypto exchange
how to sell pi coins on Bitmart crypto exchangehow to sell pi coins on Bitmart crypto exchange
how to sell pi coins on Bitmart crypto exchange
 
APP I Lecture Notes to students 0f 4the year
APP I  Lecture Notes  to students 0f 4the yearAPP I  Lecture Notes  to students 0f 4the year
APP I Lecture Notes to students 0f 4the year
 
how to sell pi coins at high rate quickly.
how to sell pi coins at high rate quickly.how to sell pi coins at high rate quickly.
how to sell pi coins at high rate quickly.
 
Isios-2024-Professional-Independent-Trustee-Survey.pdf
Isios-2024-Professional-Independent-Trustee-Survey.pdfIsios-2024-Professional-Independent-Trustee-Survey.pdf
Isios-2024-Professional-Independent-Trustee-Survey.pdf
 
The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.The secret way to sell pi coins effortlessly.
The secret way to sell pi coins effortlessly.
 
Introduction to Indian Financial System ()
Introduction to Indian Financial System ()Introduction to Indian Financial System ()
Introduction to Indian Financial System ()
 
USDA Loans in California: A Comprehensive Overview.pptx
USDA Loans in California: A Comprehensive Overview.pptxUSDA Loans in California: A Comprehensive Overview.pptx
USDA Loans in California: A Comprehensive Overview.pptx
 
when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.when will pi network coin be available on crypto exchange.
when will pi network coin be available on crypto exchange.
 
what is the future of Pi Network currency.
what is the future of Pi Network currency.what is the future of Pi Network currency.
what is the future of Pi Network currency.
 
PF-Wagner's Theory of Public Expenditure.pptx
PF-Wagner's Theory of Public Expenditure.pptxPF-Wagner's Theory of Public Expenditure.pptx
PF-Wagner's Theory of Public Expenditure.pptx
 

Richard Victor

  • 1. Compliance with Narcotics Guidelines April 10-12, 2012 Walt Disney World Swan Resort
  • 2. Accepted Learning Objectives: 1.  Describe how managed care programs, employers, health care providers and insurers are susceptible to increased workers compensation costs due to prescription drug abuse. 2.  Identify strategies employers and medical professionals can use to help drug-dependent and addicted employees regain control of their lives and return to work using results of CompPharma’s survey, “Prescription Drug Management in Workers’ Compensation – The Eighth Annual Survey.” 3.  Describe how Washington State has addressed the over use of opioids in workers’ compensation.
  • 3. Disclosure Statement •  Joseph Paduda has disclosed that he has a relationship with Reckitt Benckiser’s Suboxone Sublingual Film. •  Dr. Richard A. Victor has disclosed no relevant, real or apparent personal or professional financial relationships.
  • 4. Narcotics Use And Compliance With Guidelines Richard Victor, J.D., Ph.D. Executive Director Workers Compensation Research Institute
  • 5. Today s Outline •  About heath care in workers compensation •  Relevant findings from 2 WCRI studies •  About WCRI
  • 6. About Workers Compensation •  Century-old social program •  Injured workers receive medical care, income benefits, rehabilitation •  Patients entitled by law to all necessary care •  Patients have no deductibles or copayments, no formularies or step therapy •  Physician dispensing is common in a growing number of states •  Prices near AWP
  • 7. Workers Compensation Facts •  Employers pay $79 billion in 2008 •  Medical care represents more than half of the cost •  4.6 million work-injuries •  2.3 million involve lost time from work •  20% of total—lost more than 1 week from work •  Median lost time is 16 weeks
  • 8. Common Medical Conditions In Workers Compensation Medical Condition % Of Cases Spine conditions Sprain, strain and nonspecific spine pain 21% Neurologic spine pain 7% Other musculoskeletal conditions Non-spine sprain and strain 15% Shoulder inflammation 7% Knee derangement 4% Carpal tunnel syndrome 2% Trauma Fractures 10% Laceration or contusion 12% Other conditions 21% Cases With > 7 Days Of Lost Time
  • 9. Today s Outline •  About heath care in workers compensation  Relevant findings from 2 WCRI studies •  About WCRI
  • 10. Two WCRI Studies Of Area Variations In Prescribing Patterns
  • 11. Major Findings From WCRI Narcotics Studies
  • 12. Data •  Nonsurgical cases •  Patients lost more than 1 week from work •  Results presented for episodes of disability •  Snapshot at an average of 24 months after injury
  • 13. Data •  17 states that represent more than 60% of WC benefits in the U.S. •  360,000 Rx for 75,000 nonsurgical episodes of disability •  16% to 50% of all episodes in each state
  • 14. Most Patients Get Rx Pain Medication Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 15. Most Patients Get Narcotics Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 16. Unusually High Use Of Narcotics In NY, LA, PA, And MA Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 17. Also Higher Use Of Narcotics In CA, MD, NC, And TX Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 18. Average Worker In Four States Had More Narcotic Pills Per Episode Of Disability Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 19. Practice Patterns Favor Schedule II Narcotics In Northeast & Mid-Atlantic States Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 20. Major Findings From WCRI Narcotics Studies
  • 21. Longer-Term Use Of Narcotics •  Study definition –  First narcotic Rx filled within first 3 months after injury –  Narcotics continued after 6 months post-injury –  3+ Rx fills during months 7–12 •  Nonsurgical cases
  • 22. Longer-Term Use Common In Louisiana And New York Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 23. Longer-Term Use Also More Likely In PA, TX, CA, MA, And NC Nonsurgical Claims With > 7 Days Of Lost Time, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 24. VeryModest Interstate Variation In At Substantial Interstate Variation Substantial Interstate Variation Median MEUs 90thEpisode of Disability The Per Percentile 50th Percentile 75th Percentile 90th Percentile Morphine Equivalent Units Per Claim Nonsurgical Claims With > 7 Days Of Lost Time That Were Identified As Longer-Term Users Of Narcotics, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 25. Common Guideline Recommendations For Monitoring & Management
  • 26. Few Longer-Term Users Received Services For Monitoring/Management Nonsurgical Claims With > 7 Days Of Lost Time That Were Identified As Longer-Term Users Of Narcotics, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 27. Few Longer-Term Users Received Services For Monitoring/Management Nonsurgical Claims With > 7 Days Of Lost Time That Were Identified As Longer-Term Users Of Narcotics, Injuries From October 2005 To September 2006, Prescriptions Filled Through March 2008
  • 28. Today s Outline •  About heath care in workers compensation •  Relevant findings from 2 WCRI studies  About WCRI
  • 29. About WCRI •  Nation s largest independent think tank on workers compensation public policy issues •  Published hundreds of peer-reviewed studies since founding in 1983 •  Membership organization—diverse •  Not make recommendations nor take positions on issues
  • 30. About WCRI: Focus Of Current Health Policy Research Agenda
  • 31. About WCRI: Focus Of Current Health Policy Research Agenda